The development of the Biosimilars market is growing exponentially with the industry forecast to be worth $25 billion by 2020. With the regulatory landscape evolving rapidly, it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between Europe and the US. With Europe leading the way in the field of Biosimilar development, it is important to get to grips with all areas in the product lifecycle from early stage developments, protein characterisation and analytical comparability to patent litigation, market access, pricing and reimbursement through to emerging markets and global developments. Every angle should be considered and taken account for through the development process and with the EU the most advanced market for biosimilars, accounting for 80% of global spending on these molecules, the learning curve for biosimilars is essentially still building and there are hurdles to overcome.
Against this backdrop, SMi’s 6th annual Biosimilars and Biobetters conference features a distinguished line-up of speakers who are pioneering the way in biosimilars and biobetters, including MHRA, GfK, Teva, Harvest Moon Pharmaceuticals USA Inc and many more, as they present on the latest development on key topics including regulatory landscape, pharmacovigilance of biosimilars, patent litigation, market access and EU & global market developments.
Benefits of attending:
- Hear the latest on the evolving regulatory biosimilar landscape and review the guidelines
- Gain understanding on the barriers being faced for market access and commercialisation of products through case-study led presentations
- Focus on the global market developments with case studies on the emerging markets of biosimilars and assessing the trends we are currently seeing
- Assess and review in-depth protein characterisation and analytical comparability to efficiently and effectively collect data
Speaker Panel include:
- Chairperson: Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc
- Shahin Kauser, Senior Scientific Assessor, MHRAChris Teale, Vice President Europe, GfK NOP Ltd
- Bracha Timan, Director, Israel Site Head, Global Bioassays & Technology, Global R&D, Teva
- Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
- Karsten Roth, Director Clinical Operations, Cinfa Biotech GmbH
- Alan Sheppard, Principal, Global Generics and Biosimilars, IMS Health
- Steinar Madsen, Medical Director, Norwegian Medicines Agency
View the full speaker line-up, two-day conference programme and register online at http://www.biosimilars-biobetters.co.uk/selectscience
For further information, please contact Fateja Begum on tel +44 20 7827 6184 or email fbegum@smi-online.co.uk